title: Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.
abstract: Although statins and other pharmacological approaches have improved the management of lipid abnormalities, there exists a need for newer treatment modalities especially for the management of hypertriglyceridemia. Lipoprotein lipase (LPL), by promoting hydrolytic cleavage of the triglyceride core of lipoproteins, is a crucial node in the management of plasma lipid levels. Although LPL expression and activity modulation is observed as a pleiotropic action of some the commonly used lipid lowering drugs, the deliberate development of drugs targeting LPL has not occurred yet. In this review, we present the biology of LPL, highlight the LPL modulation property of currently used drugs and review the novel emerging approaches to target LPL.
authors: Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26505, USA.
authors: Werner J
authors: WJ
authors: Geldenhuys
authors: Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, USA.
authors: Li
authors: L
authors: Lin
authors: Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, USA.
authors: Altaf S
authors: AS
authors: Darvesh
authors: Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, USA. Electronic address: psadana@neomed.edu.
authors: Prabodh
authors: P
authors: Sadana
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D008071:Lipoprotein Lipase / Q000737:chemistry / Q000378:metabolism*; D008659:Metabolic Diseases / Q000188:drug therapy / Q000201:enzymology*
chemical_list: D008071:Lipoprotein Lipase